The clinical burden of prostate cancer in Canada: Forecasts from the Montreal Prostate Cancer Model

CMAJ. Canadian Medical Association Journal

Volumn 162, Issue 7, 2000, Pages 977-983

  Graver, Steven A ^a   Coupai, Louis ^a   Zowall, Hanna ^b   Rajan, Raghu ^c   Trachtenberg, John ^d   Elhilali, Mostafa ^a   Chetner, Michael ^b   Goldenberg, Larry ^c  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE;

ARTICLE; CANADA; CANCER SURVIVAL; COHORT ANALYSIS; FORECASTING; HORMONAL THERAPY; HUMAN; INCIDENCE; LIFE EXPECTANCY; MALE; MODEL; PROSTATE CANCER; PROSTATECTOMY; VALIDATION PROCESS;

EID: 0034603845     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Coley CM, Barry- MJ, Fleming C, Mulley AG. Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. American College of Physicians, [renew] Ann Intern Med 1997;126:394-406.
2. Mettlin CJ, Murphy GP, Ho R, Menck HR. The National Cancer Data Base report on longitudinal observations on prostate cancer. Cancer 1996;77:2162-6.
3. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. Cancer J Clin 1996;46(l):S-27.
4. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548-52.
5. Chamberlain J, Melia J, Moss S, Brown J. Report prepared for the Health Technology Assessment Panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales [renew]. BrJ Urol 1997;79(3 Suppl):1-32.
6. Barry AIJ, Fleming C, Cole)- CM, Wasson JH, Fahs MC, OesterlingJE. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part I: Framing the debate. Urology 1995;46(1):2-13.
7. Barry MJ, Fleming C, Coley CM, Wasson JH, Fahs MC, Oesterling JE. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part III: Management strategies and outcomes. Urology 1995;46(3):277-89.
8. Grover SA, Zowall H, Coupai L, Krahn MD. The economic burden of prostate cancer in Canada. CMAJ 1999;160(5):685-90.
9. Grover SA, Coupai L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, et al. The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. CAL472000;162(7):987-92.
10. Beck JR, Pauker SG. The Markov process in medical prognosis. Mal Dais Mating 1983;3:419-58.
11. Sonnenberg FA, Beck JR. Markov models in medical decision making: A practical guide. MeJ Dccis Making 199J;H:122-18.
12. Alellinger GT, Gleason D, Bailar J III. The histology and prognosis of prostatic cancer. J Ural 1967;97:331-7.
13. Zincke H. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adcnocarcinomas of the prostate with 5 years of follow-up [letter]. J Urol 1994;151:435.
14. Cancer in Canada 1991. Ottawa: Health Statistics Division, Statistics Canada; 1995. Cat no 82-218.
15. Mettlin CJ, Murphy GP, McGinnis LS, Menck HR. The National Cancer Data Base report on prostate cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1995;76:1104-12.
16. Lu-Yao GL, McLerran D, Wasson J, WennbergJE. An assessment of radical prostatectomy: Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA 1993;269:2633-6.
17. Lubke WL, Optenbcrg SA, Thompson IM. Analysis of the first-year cost of a prostate cancer screening and treatment program in the United States. J Natl Cancer Ina 1994;86:1790-2.
18. Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley AG Jr, Wennberg J. A structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team [published erratum appears m Arch FamMed 1993;2(10):I030].^r(rA FamMcJ 1993;2:487-93.
19. Fowler FJ Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg E. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology 1993;42:622-9.
20. Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiât Onto!BiolPbys 1991;21:935-9.
21. Mettlin CJ, Murphy G. The National Cancer Data Base report on prostate cancer. Cancer 1994;74:1640-8.
22. Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg J. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. JNatl Cancer Inst 1996;88:166-73.
23. Fowler FJ Jr, Barry MJ, Lu-Yao G, Wasson JH, Bin L. Outcomes of external-beam radiation therapy for prostate cancer: a study of Aledicare beneficiaries in three surveillance, epidemiology, and end results areas. J Clin Oncol 1996;14:2258-65.
24. Gerber GS, Thisted RA, Scardino PT, Frohmuller HG, Schroeder FH, Paulson DF, et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 1996;276:615-9.
25. Chodak GW, Thisted RA, Gerber GS, Johansson JE, AdolfssonJ, Jones GW, et al. Results of conservative management of clinically localized prostate cancer. NEnglJMed 1994;330:242-8.
26. Perez CA, Pilepich MV, Garcia D, Simpson JR, Zivnuska F, Hederman AIA. Definitive radiation therapy in carcinoma of the prostate localized to the pelvis: Experience at the Mallinckrodt Institute of Radiology. NCl Monogr 1988;7:85-94.
27. Lee RJ, Sause WT. Surgically staged patients with prostatic carcinoma treated with definitive radiotherapy: fifteen-year results. Urology 1994;43:640-4.
28. Johansson JE, Holmberg L, Johansson S, Bcrgstrom R, Adami HO. Fifteenyear survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997;277:467-71.
29. Life talks, Canada and provinces 1990-1992. Ottawa: Statistics Canada; 1995. Cat no 84-537.
30. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localized prostate cancer. Lancet 1997;349:906-10.
31. Albcrtsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995;274(8):626-31.
32. Zagars GK, von Eschenbach AC, Johnson DE, Oswald AIJ. Stage C Adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer 1987;60:1489-99.
33. Cowen AIE, Chartrand AI, Weitzcl WF. A Alarkov model of the natural history of prostate cancer. JClin EpiJaaiol 1994;47:3-21.
34. Fleming C, Wasson JII, Albertsen PC, Barry AIJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA 1993;269:2650-8.
35. Screening for cancer of prostate: An evaluation of benefits, unwanted health effects ana costs. Alontreal: Conseil d'évaluation des technologies de la santé du Québec; 1995.
36. Krahn AID, Alahoney JE, Eckman AH I, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer. A decision analytic view. JAMA 1994;272:773-80.
37. Cost and effectiveness of prostate cancer screening in elderly men. Washington: Office of Technology Assessment, Congress of the United States; 1995. Publ no OTA-BP-H-154.